• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

使用基于索赔的算法来估计医疗保险人群中多发性硬化症的疾病严重程度。

Use of a claims-based algorithm to estimate disease severity in the multiple sclerosis Medicare population.

作者信息

Toliver Joshua C, Barner Jamie C, Lawson Kenneth A, Rascati Karen L

机构信息

The University of Texas at Austin, College of Pharmacy, Health Outcomes Division, 2409 University Avenue, STOP, Austin, TX A1930, United States.

出版信息

Mult Scler Relat Disord. 2021 Apr;49:102741. doi: 10.1016/j.msard.2021.102741. Epub 2021 Jan 7.

DOI:10.1016/j.msard.2021.102741
PMID:33476882
Abstract

BACKGROUND/OBJECTIVE: To compare algorithm determined disease severity, risk of multiple sclerosis (MS) relapse, and MS-related hospitalization between the age-eligible and disability-eligible MS Medicare populations.

METHODS

Using the Humana claims dataset (2013 - 2015), patients were divided into Medicare age-eligible and disability-eligible groups. A previously developed algorithm, which used MS symptoms and healthcare utilization to categorize MS disease severity into three groups (low, moderate, high) at baseline was employed. Flexible parametric and Cox proportional hazard models were used to estimate the risk for MS relapses and MS-related hospitalizations among the MS disease severity groups and the two eligibility cohorts in the follow-up period.

RESULTS

Of the overall sample (N = 6,559), the majority (N = 4,813, 73.4%) were disability-eligible and in the low disease severity group (N = 4,468, 68.1%). In 10 of 16 disease severity algorithm predictors, the prevalence of these predictors was significantly (p<0.001) higher in the disability-eligible group compared to the age-eligible group. Survival analyses revealed that the disability-eligible group had a significantly higher risk for follow-up MS relapses and follow-up MS-related hospitalizations (HR = 1.79 [CI 1.54 - 2.08] and HR = 1.38 [CI 1.11-1.72], respectively) compared to those in the age-eligible group. When both eligibility and disease severity were considered in the model increases in hazard ratios corresponded generally to increases in disease severity. However, the type of Medicare eligibility does not appear to have a clear pattern across MS disease severity groups for either MS relapse or hospitalizations, CONCLUSION: The disability-eligible Medicare population had a significantly higher prevalence of MS comorbidities and higher MS severity scores at baseline. In addition, they had a higher risk for MS-related relapses and MS-related hospitalizations in the follow-up period. It is important to account for disability status when assessing disease severity and healthcare utilization.

摘要

背景/目的:比较符合年龄标准和符合残疾标准的多发性硬化症(MS)医疗保险人群中,通过算法确定的疾病严重程度、MS复发风险和与MS相关的住院情况。

方法

利用Humana索赔数据集(2013 - 2015年),将患者分为符合医疗保险年龄标准组和符合残疾标准组。采用先前开发的一种算法,该算法在基线时使用MS症状和医疗保健利用情况将MS疾病严重程度分为三组(低、中、高)。在随访期内,使用灵活参数模型和Cox比例风险模型来估计MS疾病严重程度组以及两个符合标准队列中MS复发和与MS相关住院的风险。

结果

在总体样本(N = 6559)中,大多数(N = 4813,73.4%)符合残疾标准且处于疾病严重程度低分组(N = 4468,68.1%)。在16个疾病严重程度算法预测指标中的10个指标上,与符合年龄标准组相比,符合残疾标准组中这些预测指标的患病率显著更高(p<0.001)。生存分析显示,与符合年龄标准组相比,符合残疾标准组在随访期内MS复发和与MS相关住院的风险显著更高(风险比分别为1.79 [可信区间1.54 - 2.08]和1.38 [可信区间1. — 1.72])。当在模型中同时考虑符合标准情况和疾病严重程度时,风险比的增加通常与疾病严重程度的增加相对应。然而,对于MS复发或住院情况,医疗保险符合标准类型在MS疾病严重程度组中似乎没有明显模式。

结论

符合残疾标准的医疗保险人群在基线时MS合并症的患病率显著更高,MS严重程度评分也更高。此外,他们在随访期内与MS相关的复发和与MS相关的住院风险更高。在评估疾病严重程度和医疗保健利用情况时,考虑残疾状况很重要。

相似文献

1
Use of a claims-based algorithm to estimate disease severity in the multiple sclerosis Medicare population.使用基于索赔的算法来估计医疗保险人群中多发性硬化症的疾病严重程度。
Mult Scler Relat Disord. 2021 Apr;49:102741. doi: 10.1016/j.msard.2021.102741. Epub 2021 Jan 7.
2
Replication of a Claims-based Algorithm to Estimate Multiple Sclerosis Disease Severity in a Commercially Insured Population.基于索赔的算法在商业保险人群中估计多发性硬化症严重程度的复制。
Mult Scler Relat Disord. 2020 Nov;46:102539. doi: 10.1016/j.msard.2020.102539. Epub 2020 Sep 28.
3
Disease-Modifying Therapy Adherence and Associated Factors in a National Sample of Medicare Patients With Multiple Sclerosis.医疗保险患者多发性硬化症患者的疾病修正治疗依从性及其相关因素的全国性样本研究。
Value Health. 2020 Mar;23(3):328-334. doi: 10.1016/j.jval.2019.10.011. Epub 2019 Dec 9.
4
Healthcare resource use and relapses with fingolimod versus natalizumab for treating multiple sclerosis: a retrospective US claims database analysis.用于治疗多发性硬化症的芬戈莫德与那他珠单抗的医疗资源使用及复发情况:一项美国索赔数据库回顾性分析
Curr Med Res Opin. 2014 Aug;30(8):1461-71. doi: 10.1185/03007995.2014.915802. Epub 2014 May 2.
5
Direct and indirect cost burden associated with multiple sclerosis relapses: excess costs of persons with MS and their spouse caregivers.与多发性硬化症复发相关的直接和间接成本负担:多发性硬化症患者及其配偶照顾者的超额成本。
J Neurol Sci. 2013 Jul 15;330(1-2):71-7. doi: 10.1016/j.jns.2013.04.007. Epub 2013 May 3.
6
Development and validation of a claims-based measure as an indicator for disease status in patients with multiple sclerosis treated with disease-modifying drugs.基于索赔数据的指标用于评估接受疾病修正药物治疗的多发性硬化症患者疾病状态的开发与验证
BMC Neurol. 2017 Jun 5;17(1):106. doi: 10.1186/s12883-017-0887-1.
7
The effect of out-of-pocket costs on initiation of disease-modifying therapies among medicare beneficiaries with multiple sclerosis.自付费用对患有多发性硬化症的医疗保险受益人群启动疾病修正治疗的影响。
Mult Scler Relat Disord. 2020 Nov;46:102554. doi: 10.1016/j.msard.2020.102554. Epub 2020 Oct 1.
8
Association of Inflammation and Disability Accrual in Patients With Progressive-Onset Multiple Sclerosis.炎症与进展性多发性硬化患者残疾累积的相关性。
JAMA Neurol. 2018 Nov 1;75(11):1407-1415. doi: 10.1001/jamaneurol.2018.2109.
9
The Framingham cardiovascular risk score and 5-year progression of multiple sclerosis.弗雷明汉心血管风险评分与多发性硬化症的 5 年进展。
Eur J Neurol. 2021 Mar;28(3):893-900. doi: 10.1111/ene.14608. Epub 2020 Nov 21.
10
Thirty-day readmissions in multiple sclerosis: An age and gender-based US national retrospective analysis.多发性硬化症 30 天再入院率:基于年龄和性别的美国全国回顾性分析。
Mult Scler Relat Disord. 2019 Jun;31:41-50. doi: 10.1016/j.msard.2019.03.012. Epub 2019 Mar 20.

引用本文的文献

1
Comparative Effectiveness of Fumarates Versus Sphingosine-1-Phosphate Receptor Modulators in Black Patients with Multiple Sclerosis.富马酸盐与1-磷酸鞘氨醇受体调节剂对黑人多发性硬化症患者的疗效比较
Neurol Ther. 2025 Jun 16. doi: 10.1007/s40120-025-00774-2.
2
Real-World Treatment Outcomes in Black, Hispanic, Asian, and White People with Multiple Sclerosis Treated with Fumarates in the USA.美国使用富马酸盐治疗的黑人、西班牙裔、亚裔和白人多发性硬化症患者的真实世界治疗结果
Neurol Ther. 2025 Jun 16. doi: 10.1007/s40120-025-00773-3.
3
Clinical characteristics and treatment outcomes in multiple sclerosis patients treated with anti-CD20s who switched to fumarates: a retrospective analysis of a US healthcare claims database.
改用富马酸盐治疗的接受抗CD20治疗的多发性硬化症患者的临床特征和治疗结果:一项对美国医疗保健索赔数据库的回顾性分析
J Comp Eff Res. 2025 Mar;14(3):e240071. doi: 10.57264/cer-2024-0071. Epub 2025 Feb 12.
4
Claims-based algorithm to estimate the Expanded Disability Status Scale for multiple sclerosis in a German health insurance fund: a validation study using patient medical records.基于理赔数据的算法用于估算德国某健康保险基金中多发性硬化症患者的扩展残疾状态量表:一项使用患者病历的验证研究
Front Neurol. 2023 Dec 7;14:1253557. doi: 10.3389/fneur.2023.1253557. eCollection 2023.
5
Assessing treatment switch among patients with multiple sclerosis: A machine learning approach.评估多发性硬化症患者的治疗转换:一种机器学习方法。
Explor Res Clin Soc Pharm. 2023 Jul 10;11:100307. doi: 10.1016/j.rcsop.2023.100307. eCollection 2023 Sep.
6
Development and Internal Validation of a Disability Algorithm for Multiple Sclerosis in Administrative Data.行政数据中多发性硬化症残疾算法的开发与内部验证
Front Neurol. 2021 Nov 2;12:754144. doi: 10.3389/fneur.2021.754144. eCollection 2021.
7
COVID-19 severity and outcome in multiple sclerosis: Results of a national, registry-based, matched cohort study.COVID-19 严重程度和多发性硬化症结局:一项全国性、基于登记、匹配队列研究的结果。
Mult Scler Relat Disord. 2021 Oct;55:103217. doi: 10.1016/j.msard.2021.103217. Epub 2021 Aug 16.
8
Association between multiple sclerosis disease severity and adherence to disease-modifying therapies.多发性硬化症疾病严重程度与疾病修正治疗的依从性之间的关联。
J Manag Care Spec Pharm. 2021 Jul;27(7):915-923. doi: 10.18553/jmcp.2021.27.7.915.